Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -4490.89% is 193% below its 1-year average of -1532.37%, near the low end of its 1-year range (-4597.11%–0.00%).
95.38% below its 12-month average of -2298.56%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -4597.11%.
NET PROFIT MARGIN
-4490.89%
NET PROFIT MARGIN AVG TTM
-2298.56%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-95.38%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 568 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$756.25M
Net Profit Margin
-4490.89%
TTM Avg
-2298.56%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$761.30M
Net Profit Margin
-38.98%
TTM Avg
-18.01%
3Y Avg
-10.19%
5Y Avg
-2.91%
Market Cap
$766.87M
Net Profit Margin
-34.17%
TTM Avg
-136.69%
3Y Avg
-25443.25%
5Y Avg
-23332.75%
Market Cap
$770.68M
Net Profit Margin
-147.38%
TTM Avg
-372.93%
3Y Avg
-22199.44%
5Y Avg
-19748.48%
Market Cap
$777.46M
Net Profit Margin
1.92%
TTM Avg
0.94%
3Y Avg
-28.83%
5Y Avg
-18.64%
Market Cap
$749.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$742.96M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3758.80%
5Y Avg
-9679.73%
Market Cap
$797.93M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
Market Cap
$804.95M
Net Profit Margin
-14.52%
TTM Avg
7.87%
3Y Avg
-15.98%
5Y Avg
-254.57%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $756.25M | -4490.89% | -2298.56% | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $761.30M | -38.98% | -18.01% | -10.19% | -2.91% |
| Geron Corporation (GERN)vs › | $766.87M | -34.17% | -136.69% | -25443.25% | -23332.75% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | -147.38% | -372.93% | -22199.44% | -19748.48% |
| Mesa Laboratories, Inc. (MLAB)vs › | $777.46M | 1.92% | 0.94% | -28.83% | -18.64% |
| Design Therapeutics, Inc. (DSGN)vs › | $749.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Candel Therapeutics, Inc. (CADL)vs › | $742.96M | 0.00% | 0.00% | -3758.80% | -9679.73% |
| AdaptHealth Corp. (AHCO)vs › | $797.93M | -7.58% | 0.29% | -4.57% | -4.54% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $804.95M | -14.52% | 7.87% | -15.98% | -254.57% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $716.99M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
Operating Margin
-4974.7%
Net Profit Margin
-4490.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -4597.11% |
| 2026-03-31 | 0.00% |
| 2025-03-31 | 0.00% |
